Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant

ConclusionsThe novel eliapixant formulation substantially improved bioavailability compared with immediate-release eliapixant and may be administered with/without food.Clinical Trial RegistrationClinicaltrials.gov: NCT03773068 (initial registration: 12 December 2018).
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research